Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2024
• Main ID: NCT02500316
• Date of registration: 12/07/2015
• Prospective Registration: No
• Primary sponsor: OPKO Health, Inc.
• Public title: Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
• Scientific title: Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily R-human Growth Hormone (hGH) Therapy in Pre-pubertal Growth Hormone Deficient Children
• Date of first enrolment: February 2013
• Target sample size: 48
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/ct2/show/NCT02500316
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Belarus, Greece, Hungary, Russian Federation, Slovakia, Ukraine, United States

Contacts

• Name: Zvi Zadik, MD
• Affiliation: Kaplan Medical Center, Israel

Key inclusion & exclusion criteria

Inclusion Criteria:

Patients who completed the first year of treatment in the main study are allowed to enter
the (Long Term) Open Label Extension (OLE) study.

Exclusion Criteria:

1. Children with past or present intracranial tumor growth as confirmed by an MRI scan
(with contrast).

2. History of radiation therapy or chemotherapy.

3. Malnourished children defined as:

1. Serum albumin below the lower limit of normal (LLN) according to the reference
ranges of central laboratory;

2. Serum iron below the lower limit of normal (LLN) according to the reference
ranges of central laboratory;

3. BMI < -2 Standard Deviation for age and sex;

4. Children with psychosocial dwarfism.

5. Children born small for gestational age (SGA - birth weight and/or birth length < -2
SD for gestational age).

6. Presence of anti-hGH antibodies at screening.

7. Any clinically significant abnormality likely to affect growth or the ability to
evaluate growth, such as, but not limited to, chronic diseases like renal
insufficiency, spinal cord irradiation, etc.

8. Patients with diabetes mellitus.

9. Patients with impaired fasting sugar (based on WHO; fasting blood sugar >110 mg/dl or
6.1 mmol/l) after repeated blood analysis.

10. Chromosomal abnormalities and medical "syndromes" (Turner's syndrome, Laron syndrome,
Noonan syndrome, Prader-Willi Syndrome, Russell-Silver Syndrome, short stature
homeobox-containing gene (SHOX) mutations/deletions and skeletal dysplasias), with the
exception of septo-optic dysplasia.

11. Closed epiphyses.

12. Concomitant administration of other treatments that may have an effect on growth such
as anabolic steroids and methylphenidate for attention deficit hyperactivity disorder
(ADHD), with the exception of hormone replacement therapies (thyroxine,
hydrocortisone, desmopressin (DDAVP))

13. Children requiring glucocorticoid therapy (e.g. asthma) who are taking a dose of
greater than 400 µg/d of inhaled budesonide or equivalents for longer than 1 month
during a calendar year.

14. Major medical conditions and/or presence of contraindication to r-hGH treatment.

15. Known or suspected HIV-positive patient, or patient with advanced diseases such as
AIDS or tuberculosis.

16. Drug, substance, or alcohol abuse.

17. Known hypersensitivity to the components of study medication.

18. Other causes of short stature such as coeliac disease, hypothyroidism and rickets.

19. The patient and/or the parent/legal guardian are likely to be non-compliant in respect
to study conduct.

20. Participation in any other trial of an investigational agent within 30 days prior to
Screening.



Age minimum: 3 Years
Age maximum: 11 Years
Gender: All

Health Condition(s) or Problem(s) studied

Growth Hormone Deficiency (GHD)

Intervention(s)

Drug: MOD-4023

Primary Outcome(s)

Annual Height Velocity [Time Frame: 8 years]

Delta height SDS every 12 months [Time Frame: 8 years]

Secondary Outcome(s)

Absolute IGF-I levels on day 4 after MOD-4023 dosing [Time Frame: 8 years]

IGF-I SDS on day 4 after MOD-4023 dosing [Time Frame: 8 years]

Secondary ID(s)

CP-4-004-extension

2011-004553-60

Source(s) of Monetary Support

Please refer to primary and secondary sponsors